| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.
|
Nat Rev Clin Oncol
|
2013
|
2.64
|
|
2
|
Dendritic-cell-based therapeutic cancer vaccines.
|
Immunity
|
2013
|
2.29
|
|
3
|
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.
|
J Immunother Cancer
|
2015
|
1.62
|
|
4
|
Trial watch: Dendritic cell-based interventions for cancer therapy.
|
Oncoimmunology
|
2012
|
1.51
|
|
5
|
Control of the immune response by pro-angiogenic factors.
|
Front Oncol
|
2014
|
1.26
|
|
6
|
Adjuvant therapy for renal cell carcinoma: past, present, and future.
|
Oncologist
|
2014
|
1.11
|
|
7
|
Recent developments in the treatment of renal cell carcinoma.
|
Ther Adv Urol
|
2013
|
1.05
|
|
8
|
Therapeutic cancer vaccines: past, present, and future.
|
Adv Cancer Res
|
2013
|
0.99
|
|
9
|
Cancer immunotherapy in clinical practice -- the past, present, and future.
|
Chin J Cancer
|
2014
|
0.98
|
|
10
|
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.
|
Br J Cancer
|
2014
|
0.95
|
|
11
|
Sunitinib re-challenge in advanced renal-cell carcinoma.
|
Br J Cancer
|
2014
|
0.93
|
|
12
|
Trial watch: Dendritic cell-based anticancer therapy.
|
Oncoimmunology
|
2014
|
0.90
|
|
13
|
Contemporary Treatment of Metastatic Renal Cell Carcinoma.
|
Oncol Rev
|
2016
|
0.90
|
|
14
|
Optimizing dendritic cell-based approaches for cancer immunotherapy.
|
Yale J Biol Med
|
2014
|
0.85
|
|
15
|
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
|
Nat Rev Urol
|
2016
|
0.84
|
|
16
|
Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
|
Biomed Res Int
|
2015
|
0.83
|
|
17
|
Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma.
|
Hum Vaccin Immunother
|
2015
|
0.83
|
|
18
|
Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer.
|
Front Immunol
|
2013
|
0.82
|
|
19
|
Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.
|
Front Immunol
|
2015
|
0.82
|
|
20
|
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
|
Immunotherapy
|
2014
|
0.81
|
|
21
|
A new age for vaccine therapy in renal cell carcinoma.
|
Cancer J
|
2013
|
0.81
|
|
22
|
Therapeutic challenges in renal cell carcinoma.
|
Am J Clin Exp Urol
|
2015
|
0.80
|
|
23
|
Combination therapy for metastatic renal cell carcinoma.
|
Ann Transl Med
|
2016
|
0.80
|
|
24
|
Immunobiology and immunotherapy in genitourinary malignancies.
|
Ann Transl Med
|
2016
|
0.78
|
|
25
|
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.
|
Oncoimmunology
|
2015
|
0.77
|
|
26
|
Sunitinib in the treatment of metastatic renal cell carcinoma.
|
Ther Adv Urol
|
2016
|
0.77
|
|
27
|
An update on current management of advanced renal cell cancer, biomarkers, and future directions.
|
Ann Cancer Res
|
2015
|
0.76
|
|
28
|
Medical treatment of renal cancer: new horizons.
|
Br J Cancer
|
2016
|
0.76
|
|
29
|
Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.
|
P T
|
2016
|
0.75
|
|
30
|
Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives?
|
Transl Androl Urol
|
2013
|
0.75
|
|
31
|
Therapeutic cancer vaccines and combination immunotherapies involving vaccination.
|
Immunotargets Ther
|
2014
|
0.75
|